➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
Moodys
Medtronic
Harvard Business School

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

MILPROSA Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Milprosa, and when can generic versions of Milprosa launch?

Milprosa is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-five countries.

The generic ingredient in MILPROSA is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the progesterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Milprosa

A generic version of MILPROSA was approved as progesterone by FRESENIUS KABI USA on April 25th, 2001.

  Try Before You Buy

US Patents and Regulatory Information for MILPROSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc MILPROSA progesterone SYSTEM;VAGINAL 201110-001 Apr 29, 2020 DISCN Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
Ferring Pharms Inc MILPROSA progesterone SYSTEM;VAGINAL 201110-001 Apr 29, 2020 DISCN Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
Ferring Pharms Inc MILPROSA progesterone SYSTEM;VAGINAL 201110-001 Apr 29, 2020 DISCN Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
Ferring Pharms Inc MILPROSA progesterone SYSTEM;VAGINAL 201110-001 Apr 29, 2020 DISCN Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for MILPROSA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0113964 97C0037 Belgium   Try Before You Buy PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
McKinsey
Baxter
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.